全文获取类型
收费全文 | 2648篇 |
免费 | 215篇 |
专业分类
2863篇 |
出版年
2023年 | 22篇 |
2022年 | 51篇 |
2021年 | 95篇 |
2020年 | 43篇 |
2019年 | 68篇 |
2018年 | 81篇 |
2017年 | 79篇 |
2016年 | 95篇 |
2015年 | 141篇 |
2014年 | 145篇 |
2013年 | 171篇 |
2012年 | 234篇 |
2011年 | 195篇 |
2010年 | 100篇 |
2009年 | 103篇 |
2008年 | 126篇 |
2007年 | 131篇 |
2006年 | 115篇 |
2005年 | 115篇 |
2004年 | 125篇 |
2003年 | 70篇 |
2002年 | 86篇 |
2001年 | 56篇 |
2000年 | 34篇 |
1999年 | 39篇 |
1998年 | 15篇 |
1997年 | 17篇 |
1996年 | 17篇 |
1995年 | 16篇 |
1994年 | 21篇 |
1993年 | 10篇 |
1992年 | 27篇 |
1991年 | 15篇 |
1990年 | 18篇 |
1989年 | 14篇 |
1988年 | 11篇 |
1987年 | 11篇 |
1986年 | 15篇 |
1985年 | 14篇 |
1984年 | 16篇 |
1983年 | 13篇 |
1982年 | 11篇 |
1979年 | 5篇 |
1975年 | 7篇 |
1973年 | 10篇 |
1972年 | 6篇 |
1971年 | 8篇 |
1970年 | 5篇 |
1969年 | 8篇 |
1968年 | 7篇 |
排序方式: 共有2863条查询结果,搜索用时 15 毫秒
991.
Shukla K Thomas AG Ferraris DV Hin N Sattler R Alt J Rojas C Slusher BS Tsukamoto T 《Bioorganic & medicinal chemistry letters》2011,21(20):6184-6187
A series of sulfasalazine analogs were synthesized and tested for their ability to block cystine-glutamate antiporter system xc? using L-[(14)C]cystine as a substrate. Replacement of sulfasalazine's diazo group with an alkyne group led to an equally potent inhibitor, 2-hydroxy-5-((4-(N-pyridin-2-ylsulfamoyl)phenyl)ethynyl)benzoic acid 6. Our SAR studies also revealed that the carboxylate group of sulfasalazine is essential for its inhibitory activity while the phenolic hydroxyl group is dispensable. Truncated analogs lacking an N-pyridin-2-ylsulfamoyl moiety were less potent than sulfasalazine, but may serve as more tractable templates because of their low molecular weight by applying a variety of fragment growing approaches. Given that sulfasalazine is rapidly metabolized through cleavage of the diazo bond, these analogs may possess a more desirable pharmacological profile as system xc- blockers, in particular, for in vivo studies. 相似文献
992.
Mosberg JA Yep A Meredith TC Smith S Wang PF Holler TP Mobley HL Woodard RW 《Journal of bacteriology》2011,193(12):2981-2988
Previous studies showed that deletion of genes c3405 to c3410 from PAI-metV, a genomic island from Escherichia coli CFT073, results in a strain that fails to compete with wild-type CFT073 after a transurethral cochallenge in mice and is deficient in the ability to independently colonize the mouse kidney. Our analysis of c3405 to c3410 suggests that these genes constitute an operon with a role in the internalization and utilization of an unknown carbohydrate. This operon is not found in E. coli K-12 but is present in a small number of pathogenic E. coli and Shigella boydii strains. One of the genes, c3406, encodes a protein with significant homology to the sugar isomerase domain of arabinose 5-phosphate isomerases but lacking the tandem cystathionine beta-synthase domains found in the other arabinose 5-phosphate isomerases of E. coli. We prepared recombinant c3406 protein, found it to possess arabinose 5-phosphate isomerase activity, and characterized this activity in detail. We also constructed a c3406 deletion mutant of E. coli CFT073 and demonstrated that this deletion mutant was still able to compete with wild-type CFT073 in a transurethral cochallenge in mice and could colonize the mouse kidney. These results demonstrate that the presence of c3406 is not essential for a pathogenic phenotype. 相似文献
993.
Gamboa-León R Gonzalez-Ramirez C Padilla-Raygoza N Sosa-Estani S Caamal-Kantun A Buekens P Dumonteil E 《The Journal of parasitology》2011,97(2):338-343
We sought to determine the serological test that could be used for Trypanosoma cruzi seroprevalence studies in Mexico, where lineage I predominates. In a previous study among pregnant women and their newborns in the states of Yucatan and Guanajuato, we reported a 0.8-0.9% of prevalence for T. cruzi -specific antibodies by Stat-Pak and Wiener ELISA. We have expanded this study here by performing an additional non-commercial ELISA and confirming the seropositives with Western blot, using whole antigens of a local parasite strain. We found a seroprevalence of 0.6% (3/500) in Merida and 0.4% in Guanajuato (2/488). The 5 seropositive umbilical cord samples reacted to both non-commercial ELISA and Western blot tests, and only 1 of the maternal samples was not reactive to non-commercial ELISA. A follow-up of the newborns at 10 mo was performed in Yucatan to determine the presence of T. cruzi antibodies in children as evidence of congenital infection. None of the children was seropositive. One newborn from an infected mother died at 2 wk of age of cardiac arrest, but T. cruzi infection was not confirmed. The T. cruzi seroprevalence data obtained with both commercial tests (Stat-Pak and ELISA Wiener) are similar to those from non-commercial tests using a local Mexican strain of T. cruzi. 相似文献
994.
Christopher N. Carender Christopher A. Anthony Edward O. Rojas Nicolas O. Noiseux Nicholas A. Bedard Timothy S. Brown 《The Iowa orthopaedic journal》2022,42(1):169
BackgroundPreoperative counseling may reduce postoperative opioid requirements; however, there is a paucity of randomized controlled trials (RCTs) demonstrating efficacy. The purpose of this study was to perform an interventional, telehealth-based RCT evaluating the effect of peri-operative counseling on quantity and duration of opioid consumption following primary total joint arthroplasty (TJA).MethodsParticipants were randomized into three groups: 1. Control group, no perioperative counseling; 2. Intervention group, preoperative educational video; 3. Intervention group, preoperative educational video and postoperative acceptance and commitment therapy (ACT). Opioid consumption was evaluated daily for 14 days and at 6 weeks postoperatively. Best-case and worse-case intention to treat analyses were performed to account for non-responses. Bonferroni corrections were applied.Results183 participants were analyzed (63 in Group 1, 55 in Group 2, and 65 in Group 3). At 2 weeks postoperatively, there was no difference in opioid consumption between Groups 1, 2, and 3 (p>0.05 for all). At 6 weeks postoperatively, Groups 2 and 3 had consumed significantly less opioids than Group 1 (p=0.04, p<0.001) (Variable Group p-value 1. Control 2. Video Only Video + ACT Sex (n, % female) 39 (62%) 32 (58%) 40 (62%) 0.90 Surgery (n, % THA) 26 (41%) 21 (38%) 31 (47%) 0.56 Age (mean ± SD; years) 59 ± 11 59 ± 11 58 ± 9 Overall: 0.83
1v2: 0.98
2v3: 0.65
2v3: 0.56 Prolonged Opioid Use > 60 mo. (n, %) 0 0 0 - Opioid Use Within 3 mo. of Index Surgery (n, %) 0 (14%) 4 (7%) 5 (8%) 0.34
1v2: 0.98
2v3: 0.65
2v3: 0.56